Anthony M. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anthony M. Smith has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Keith P. Klugman
Respiratory and Meningeal Pathogens Research Unit, Department of Clinical Microbiology and Infectious Diseases, National Health Laboratory Service, Johannesburg, South Africa,1 Departments of International Health and Infectious Diseases, Emory University, Atlanta, Georgia2
4 shared publicationsHendrik J. Koornhof
MRC/SAIMR/WITS Pneumococcal Diseases Research Unit, Department of Clinical Microbiology and Infectious Diseases, South African Institute for Medical Research, Johannesburg,1 and Microbiology Department, Drs. du Buisson, Bruinette, and Kramer, Pretoria,2 South Africa, and Departments of International Health and Infectious Diseases, Emory University, Atlanta, Georgia3
1 shared publicationRoelof F. Botha
MRC/SAIMR/WITS Pneumococcal Diseases Research Unit, Department of Clinical Microbiology and Infectious Diseases, South African Institute for Medical Research, Johannesburg,1 and Microbiology Department, Drs. du Buisson, Bruinette, and Kramer, Pretoria,2 South Africa, and Departments of International Health and Infectious Diseases, Emory University, Atlanta, Georgia3
1 shared publication
Latest Publications
- Open Access
- 1 January 2003
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (1) , 387-389
Site-Specific Mutagenesis Analysis of PBP 1A from a Penicillin-Cephalosporin-Resistant Pneumococcal Isolate
Our mutagenesis study has investigated all amino acid mutations in the penicillin-binding domain of PBP 1A from Hungarian pneumococcal isolate 3191 to determine the importance of every mutation in the development of penicillin and cefotaxime resistance. Our data reveal that mutations at amino acid positions 574 to 577 and position 539 cause penicillin and cefotaxime resistance.
- 1 January 2003
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (1) , 387-389
Open AccessSite-Specific Mutagenesis Analysis of PBP 1A from a Penicillin-Cephalosporin-Resistant Pneumococcal Isolate
Our mutagenesis study has investigated all amino acid mutations in the penicillin-binding domain of PBP 1A from Hungarian pneumococcal isolate 3191 to determine the importance of every mutation in the development of penicillin and cefotaxime resistance. Our data reveal that mutations at amino acid positions 574 to 577 and position 539 cause penicillin and cefotaxime resistance.
- Open Access
- 1 September 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (9) , 2648-2650
Emergence of a Pneumococcal Clone with Cephalosporin Resistance and Penicillin Susceptibility
We report two South African serotype 6B pneumococcal isolates with cephalosporin resistance, yet with susceptibility to penicillin. DNA fingerprinting revealed that they were clonal in origin. pbp 2X and 1A genes showed major alterations typical of cephalosporin-resistant pneumococci. The pbp 2B gene was completely unaltered, explaining the penicillin susceptibility of the isolates.
- 1 September 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (9) , 2648-2650
Open AccessEmergence of a Pneumococcal Clone with Cephalosporin Resistance and Penicillin Susceptibility
We report two South African serotype 6B pneumococcal isolates with cephalosporin resistance, yet with susceptibility to penicillin. DNA fingerprinting revealed that they were clonal in origin. pbp 2X and 1A genes showed major alterations typical of cephalosporin-resistant pneumococci. The pbp 2B gene was completely unaltered, explaining the penicillin susceptibility of the isolates.
- Open Access
- 1 August 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (8) , 2393-2396
Alterations in MurM, a Cell Wall Muropeptide Branching Enzyme, Increase High-Level Penicillin and Cephalosporin Resistance in Streptococcus pneumoniae
We report that alteration in MurM, an enzyme involved in the biosynthesis of branched-stem cell wall muropeptides, is required for maximal expression of penicillin and cefotaxime resistance in the pneumococcus. Hungarian isolate 3191 (penicillin MIC, 16 μg/ml; cefotaxime MIC, 4 μg/ml) was a source of donor DNA in transformation experiments. Penicillin-binding protein DNA was insufficient to transform recipient strain R6 to full resistance. Further transformation with altered murM DNA was required for full expression of donor penicillin and cefotaxime resistance.
- 1 August 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (8) , 2393-2396
Open AccessAlterations in MurM, a Cell Wall Muropeptide Branching Enzyme, Increase High-Level Penicillin and Cephalosporin Resistance in Streptococcus pneumoniae
We report that alteration in MurM, an enzyme involved in the biosynthesis of branched-stem cell wall muropeptides, is required for maximal expression of penicillin and cefotaxime resistance in the pneumococcus. Hungarian isolate 3191 (penicillin MIC, 16 μg/ml; cefotaxime MIC, 4 μg/ml) was a source of donor DNA in transformation experiments. Penicillin-binding protein DNA was insufficient to transform recipient strain R6 to full resistance. Further transformation with altered murM DNA was required for full expression of donor penicillin and cefotaxime resistance.
- 1 June 2000
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 6 (2) , 105-110
Non-Penicillin-Binding Protein Mediated High-Level Penicillin and Cephalosporin Resistance in a Hungarian Clone of Streptococcus pneumoniae
A clone of Hungarian pneumococcal strains has recently been isolated with notably high levels of β-lactam resistance (penicillin MIC, 16 μg/mL; cefotaxime MIC, 4 μg/mL). The role that each penicillin-binding protein (PBP) plays in the development of resistance in these strains was investigated via transformation of susceptible strain R6 with pbp DNA from resistant strain 3191. Transformation of strain R6 with pbp2X DNA resulted in transformants with penicillin and cefotaxime MICs of 0.06 and 0.25 μg/mL, respectively. Further introduction of pbp2B and 1A DNA increased penicillin MICs to 0.25 and 4 μg/mL, respectively. Transformation of strain R6 with a combination of pbp2X and pbp1A DNA produced R6 3191/2X/1A strains with an unexpected low cefotaxime MIC of 0.5 μg/mL. This low-level of cefotaxime resistance was surprisingly increased from 0.5 to 2 μg/mL in R6 3191/2X/2B/1A strains. This suggests the involvement of altered PBP 2B in cefotaxime resistance. Therefore, within this particular setting of resistance, the environmental presence of selectors for altered PBP 2B (penicillin or piperacillin) are required for the development of high-level cefotaxime resistance. The MICs of R6 3191/2X/2B/1A strains never reached the MICs of the donor strain. Full MICs of the donor were eventually reached by transforming R6 3191/2X/2B with chromosomal 3191 DNA. Resultant transformants revealed the introduction of altered PBP 1A, while unaltered PBPs 1B, 2A, and 3 proved that these PBPs were not involved in resistance. A non-PBP resistance determinant has therefore made up the difference in resistance between R6 3191/2X/2B/1A and donor strain 3191. Beta-lactamase activity and efflux systems have so far been eliminated as causes of resistance. This resistance determinant represents a novel mechanism for β-lactam resistance in clinical isolates of pneumococci, operates at the highest level of resistance, and remains to be identified.
- 1 June 2000
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 6 (2) , 105-110
Non-Penicillin-Binding Protein Mediated High-Level Penicillin and Cephalosporin Resistance in a Hungarian Clone of Streptococcus pneumoniae
A clone of Hungarian pneumococcal strains has recently been isolated with notably high levels of β-lactam resistance (penicillin MIC, 16 μg/mL; cefotaxime MIC, 4 μg/mL). The role that each penicillin-binding protein (PBP) plays in the development of resistance in these strains was investigated via transformation of susceptible strain R6 with pbp DNA from resistant strain 3191. Transformation of strain R6 with pbp2X DNA resulted in transformants with penicillin and cefotaxime MICs of 0.06 and 0.25 μg/mL, respectively. Further introduction of pbp2B and 1A DNA increased penicillin MICs to 0.25 and 4 μg/mL, respectively. Transformation of strain R6 with a combination of pbp2X and pbp1A DNA produced R6 3191/2X/1A strains with an unexpected low cefotaxime MIC of 0.5 μg/mL. This low-level of cefotaxime resistance was surprisingly increased from 0.5 to 2 μg/mL in R6 3191/2X/2B/1A strains. This suggests the involvement of altered PBP 2B in cefotaxime resistance. Therefore, within this particular setting of resistance, the environmental presence of selectors for altered PBP 2B (penicillin or piperacillin) are required for the development of high-level cefotaxime resistance. The MICs of R6 3191/2X/2B/1A strains never reached the MICs of the donor strain. Full MICs of the donor were eventually reached by transforming R6 3191/2X/2B with chromosomal 3191 DNA. Resultant transformants revealed the introduction of altered PBP 1A, while unaltered PBPs 1B, 2A, and 3 proved that these PBPs were not involved in resistance. A non-PBP resistance determinant has therefore made up the difference in resistance between R6 3191/2X/2B/1A and donor strain 3191. Beta-lactamase activity and efflux systems have so far been eliminated as causes of resistance. This resistance determinant represents a novel mechanism for β-lactam resistance in clinical isolates of pneumococci, operates at the highest level of resistance, and remains to be identified.